Challenging perceptions. Transforming innovations. Changing lives.
We collaborate with the most exciting sci-entrepreneurs to help transform bold visions into thriving companies that improve people’s lives.
Life changing Science
Building successful life sciences and healthcare ventures is technically challenging, pricey and unpredictable. Too often we’ve seen them fail to reach the public sphere.
We have developed the knowledge, network and tools to help founders overcome these challenges and ensure valuable science is translated into tangible technologies.
From concept to market
We invest time, resources and capital to de-risk and fast-track your development. Whether you have the seed of a scientific innovation or are building your proof of concept, our multi-phase framework is designed to help you translate your vision into a thriving business.
What we offer
- Non-dilutive translational funding and equity investment packages
- Commercialisation and business development services
- Design, development and prototyping of scientific proofs-of-concepts
- Executive mentorship and global network
- Lab and office space
Our story so far
300+
Startups
20%
Secured > £500k in seed investments
c.£1B
Combined value of top 55 ventures
Our startups founders
DJS Antibodies
DJS Antibodies’ proprietary antibody discovery technology delivers unprecedented success rates in the discovery of functional antibodies to GPCRs. Built on a deep understanding of immunology and antibody production it enables them to discover functional antibodies to complex protein targets. Co-founders Joe and David joined Panacea Stars in 2016 while completing their respective DPhil at the University of Oxford. DJS antibodies was acquired in 2022 by AbbVie forM in addition to milestone payments.
Enterobiotix
Enterobiotix are leveraging the untapped potential of the human microbiome to develop novel medicinal products that restore health and prevent disease, with an initial focus on infections caused by antibiotic-resistant bacteria. They are developing and advancing three core product portfolios that build on the science of faecal microbiota transplantation. Founder James started the company as a medical student and joined Panacea Stars in 2017, taking home Panacea Stars Develop phase prize package for that year. The company is now flourishing and have secured over £20M in funding.
Phenomic AI
Phenomic AI accelerates drug discovery with AI. They combine machine learning and phenotypic screening to unlock key discoveries that will advance medicine in the next decade. Co-founders Sam and Oren joined Panacea Stars in 2018 and raised c.$10M since then.
Mytos (Cytera CellWorks)
Mytos builds machines that automate the growing of human and animal cells. Formerly Cytera CellWorks, Ignacio, Ali and Henry joined Panacea Stars in 2017 and subsequently participated in Y Combinator. To date, they’ve raised more than $15M.
Feebris
Feebris uses AI for precision detection of complex respiratory conditions. Feebris’ software platform connects to existing medical sensors, and can be used intuitively by non-doctor users, outside the clinic, to detect respiratory issues early and avoid complications and hospitalisations. Founded in 2017 by Elina and Adam, they joined Panacea Stars in 2018 and subsequently, they secured commitments from a number of high profile investors.
VisusNano Ltd.
VisusNano Ltd. is developing a drug-eluting intraocular lens implant, for use in patients undergoing cataract surgery. Their product improves patient outcomes, obviates the need for eye drops after surgery, and avoids the need for laser treatment after surgery. Co-founders Joanna, Elodie, Philip, and Darren joined Panacea Stars in 2016 and were the winner of our competition for that year. Since then, they have raised over £11m of funding to continue growing their company.
Cambridge Cancer Genomics
Cambridge Cancer Genomics (CCG) uses advances in machine learning, AI and big data analysis to power a new type of cancer treatment regimen. Their mission is to ensure that each patient has the right treatment to beat their cancer. Co-founders John, Harry, Evaline, and Nirmesh joined Panacea Stars in 2017 shortly after creating their company. They subsequently joined the Y Combinator programme, raised $8M in seed capital and sold the company to Dante Labs in 2021.
SAVA Health (Caura)
SAVA health offers a smart device that tracks molecular signature and gives instant, personalised feedback to train smarter, predict exhaustion, provide optimal dietary plans and reduce the risk of injuries. Renato, Rafael, Gillian, Alistar and Jaime founded the company and joined Panacea Stars in 2017. They continue to flourish, securing more than £10M in venture capital funding to date. Renato and Rafael were also named Forbes 30 under 30 in 2018.
What our partners say
How do I get involved?
Sci-entrepreneurs
Learn more about which phase is right for you and how we can help you turn your scientific idea into a successful commercial venture.
Get InvolvedPartners
Become a partner, gaining access to external curated deal flow, whilst developing local intrapreneurial assets.
Become a Partner